Cargando…
Immune Checkpoint Inhibitors (Nivolumab)-Induced Enterocolitis Demonstrated on (18)Fluorine-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography
Nivolumab, an immune checkpoint inhibitor, is a humanized anti-programmed death-1 monoclonal antibody that is used for the treatment of various cancers after second-line chemotherapy. We report a 23-year-old male with relapsed Hodgkin's lymphoma Stage IV treated with nivolumab. After 3 months o...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481218/ https://www.ncbi.nlm.nih.gov/pubmed/31040539 http://dx.doi.org/10.4103/ijnm.IJNM_141_18 |
_version_ | 1783413735707115520 |
---|---|
author | Usmani, Sharjeel Rasheed, Rashid Marafi, Fahad Al Kandari, Fareeda |
author_facet | Usmani, Sharjeel Rasheed, Rashid Marafi, Fahad Al Kandari, Fareeda |
author_sort | Usmani, Sharjeel |
collection | PubMed |
description | Nivolumab, an immune checkpoint inhibitor, is a humanized anti-programmed death-1 monoclonal antibody that is used for the treatment of various cancers after second-line chemotherapy. We report a 23-year-old male with relapsed Hodgkin's lymphoma Stage IV treated with nivolumab. After 3 months of treatment, he developed watery diarrhea and cramping abdominal pain. Follow-up positron emission tomography-computed tomography scan showed complete metabolic resolution of the disease; however, there is bowel wall thickening and colonic distension with corresponding increased fluorodeoxyglucose uptake. These findings are related to immune-related adverse event associated with nivolumab treatment, i.e., secondary enterocolitis. These adverse events can be successfully treated if timely and appropriately diagnosed. |
format | Online Article Text |
id | pubmed-6481218 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-64812182019-04-30 Immune Checkpoint Inhibitors (Nivolumab)-Induced Enterocolitis Demonstrated on (18)Fluorine-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Usmani, Sharjeel Rasheed, Rashid Marafi, Fahad Al Kandari, Fareeda Indian J Nucl Med Interesting Image Nivolumab, an immune checkpoint inhibitor, is a humanized anti-programmed death-1 monoclonal antibody that is used for the treatment of various cancers after second-line chemotherapy. We report a 23-year-old male with relapsed Hodgkin's lymphoma Stage IV treated with nivolumab. After 3 months of treatment, he developed watery diarrhea and cramping abdominal pain. Follow-up positron emission tomography-computed tomography scan showed complete metabolic resolution of the disease; however, there is bowel wall thickening and colonic distension with corresponding increased fluorodeoxyglucose uptake. These findings are related to immune-related adverse event associated with nivolumab treatment, i.e., secondary enterocolitis. These adverse events can be successfully treated if timely and appropriately diagnosed. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6481218/ /pubmed/31040539 http://dx.doi.org/10.4103/ijnm.IJNM_141_18 Text en Copyright: © 2019 Indian Journal of Nuclear Medicine http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Interesting Image Usmani, Sharjeel Rasheed, Rashid Marafi, Fahad Al Kandari, Fareeda Immune Checkpoint Inhibitors (Nivolumab)-Induced Enterocolitis Demonstrated on (18)Fluorine-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography |
title | Immune Checkpoint Inhibitors (Nivolumab)-Induced Enterocolitis Demonstrated on (18)Fluorine-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography |
title_full | Immune Checkpoint Inhibitors (Nivolumab)-Induced Enterocolitis Demonstrated on (18)Fluorine-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography |
title_fullStr | Immune Checkpoint Inhibitors (Nivolumab)-Induced Enterocolitis Demonstrated on (18)Fluorine-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography |
title_full_unstemmed | Immune Checkpoint Inhibitors (Nivolumab)-Induced Enterocolitis Demonstrated on (18)Fluorine-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography |
title_short | Immune Checkpoint Inhibitors (Nivolumab)-Induced Enterocolitis Demonstrated on (18)Fluorine-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography |
title_sort | immune checkpoint inhibitors (nivolumab)-induced enterocolitis demonstrated on (18)fluorine-fluorodeoxyglucose positron emission tomography-computed tomography |
topic | Interesting Image |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481218/ https://www.ncbi.nlm.nih.gov/pubmed/31040539 http://dx.doi.org/10.4103/ijnm.IJNM_141_18 |
work_keys_str_mv | AT usmanisharjeel immunecheckpointinhibitorsnivolumabinducedenterocolitisdemonstratedon18fluorinefluorodeoxyglucosepositronemissiontomographycomputedtomography AT rasheedrashid immunecheckpointinhibitorsnivolumabinducedenterocolitisdemonstratedon18fluorinefluorodeoxyglucosepositronemissiontomographycomputedtomography AT marafifahad immunecheckpointinhibitorsnivolumabinducedenterocolitisdemonstratedon18fluorinefluorodeoxyglucosepositronemissiontomographycomputedtomography AT alkandarifareeda immunecheckpointinhibitorsnivolumabinducedenterocolitisdemonstratedon18fluorinefluorodeoxyglucosepositronemissiontomographycomputedtomography |